Our Science

Pipeline

A new class of antifungal. Powerful. Different.

Ibrexafungerp is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

At SCYNEXIS, we believe that ibrexafungerp could be essential therapy in the treatment of multiple serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and more. Learn more about our pipeline below.

Community Infections

Completed milestone Potential key milestone
Indication
2021
2022
2023
2024
2025
Treatment of Vulvovaginal Candidiasis (VVC)
Approved June 2021
Launched Sep 2021
Brexafemme
Reduction of Incidence of Recurrent VVC
Positive Data Feb 22
sNDA RVVC Filing June 22
Approved Nov 22
Treatment of VVC, Further Research

Life-Threatening Infections

Indication
2021
2022
2023
2024
2025
Invasive Candidiasis (IC) and/or Candidemia
Data H1:24
NDA Filing H1:24
FDA Decision H2:24
Refractory Invasive Fungal Infections (Designed for LPAD eligibility)
Data H1:24
NDA Filing H1:24
FDA Decision H2:24
Data H1:24
NDA Filing H1:24
FDA Decision H2:24
Invasive Aspergillosis (Combination Therapy)
IV Formulation
P1 Liposomal IV Completed
Clinical Development Liposomal IV Formulation
NDA Filing H1:25
FDA Decision H2:25

Our Science

Learn more about our commitment to protecting the world against dangerous and difficult-to-treat infectious diseases.

Learn More

Our data on invasive infections

SCYNEXIS regularly presents key infectious disease study data at top medical meetings.

Learn More